N
Nuvation Bio Inc. (NUVB)
NYQ – Real vaqt narxi. Valyuta: USD
6.43
+0.06 (0.86%)
Yopilishda: Aug 12, 2026, 3:59 PM EDT
6.30
-0.12 (-1.86%)
Bozordan keyin: Aug 12, 2026, 6:55 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
6.43
+0.06 (0.86%)
Yopilishda: Aug 12, 2026, 3:59 PM EDT
6.30
-0.12 (-1.86%)
Bozordan keyin: Aug 12, 2026, 6:55 PM EDT
Nuvation Bio Inc. klinik bosqichdagi biotexnologiya kompaniyasi bo'lib, saratonni davolash uchun mahsulot nomzodlarini ishlab chiqishga qaratilgan. Kompaniyaning asosiy mahsulot nomzodi IBTROZI (taletrectinib) bo'lib, u ROS1+ mayda hujayrali o'pka saratoni bilan og'rigan bemorlarni davolash uchun ROS1 ingibitoridir. Kompaniya, shuningdek, safusidenibni ishlab chiqmoqda, bu mutant izotsitrat dehidrogenaza 1 ning ingibitori bo'lib, u yuqori xavfli yoki yuqori darajadagi IDH1-mutant astrositomani safusidenibga qarshi platsebo bilan parvarishlash davolash uchun 3-bosqichli klinik sinovlarda. Kompaniya 2018-yilda tashkil etilgan va uning shtab-kvartirasi Nyu-York, Nyu-Yorkda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. David C. Hanley Ph.D. | Chief Technical Operations Officer |
| Dr. David T. Hung M.D. | Founder, President, CEO & Chairman |
| Dr. Gary Hattersley Ph.D. | Chief Scientific Officer |
| Dr. Stephen Dang Ph.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Moses Makunje CPA | VP of Finance and Principal Accounting & Financial Officer |
| Mr. Philippe Pierre Sauvage | CFO & Principal Financial Officer |
| Ms. Colleen Sjogren | Chief Commercial Officer |
| Ms. Kerry A. Wentworth | Chief Regulatory Officer |
| Ms. Stacy Markel | Chief People Officer |
| Robert DeVita | Vice President of Corporate Development & Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-06 | 10-Q | nuvb-20260630.htm |
| 2026-07-06 | 8-K | d136399d8k.htm |
| 2026-06-30 | 8-K | d81296d8k.htm |
| 2026-06-29 | 305B2 | d88994d305b2.htm |
| 2026-05-27 | 8-K | d844566d8k.htm |
| 2026-05-04 | 8-K | d132166d8k.htm |
| 2026-05-04 | 10-Q | nuvb-20260331.htm |
| 2026-04-21 | DEFA14A | ef20071024_defa14a.htm |
| 2026-04-10 | DEF 14A | nuvb-20260521.htm |
| 2026-04-10 | ARS | ny20065562x2_ars.pdf |